Ibnsina Pharma (EGX:ISPH)
8.87
0.00 (0.00%)
At close: Mar 27, 2025
Ibnsina Pharma Balance Sheet
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 835.86 | 1,131 | 541.21 | 468.54 | 270.88 | Upgrade
|
Cash & Short-Term Investments | 835.86 | 1,131 | 541.21 | 468.54 | 270.88 | Upgrade
|
Cash Growth | -26.08% | 108.93% | 15.51% | 72.97% | 128.66% | Upgrade
|
Accounts Receivable | 16,267 | 9,761 | 5,775 | 5,743 | 3,267 | Upgrade
|
Other Receivables | 3.04 | 0.01 | 0.07 | - | 0.37 | Upgrade
|
Receivables | 16,270 | 9,761 | 5,775 | 5,743 | 4,831 | Upgrade
|
Inventory | 6,575 | 3,195 | 2,614 | 2,359 | 2,101 | Upgrade
|
Prepaid Expenses | 24.34 | 28.39 | 38.8 | 46.45 | 33.84 | Upgrade
|
Other Current Assets | 1,769 | 1,823 | 1,543 | 1,061 | 655.1 | Upgrade
|
Total Current Assets | 25,474 | 15,937 | 10,511 | 9,678 | 7,891 | Upgrade
|
Property, Plant & Equipment | 2,672 | 2,184 | 2,156 | 1,468 | 1,227 | Upgrade
|
Long-Term Investments | - | 15.92 | - | - | - | Upgrade
|
Other Intangible Assets | 218.37 | 219.02 | 30.18 | 15.3 | 6.9 | Upgrade
|
Long-Term Deferred Tax Assets | 228.73 | 114.4 | 82 | 59.39 | 11.58 | Upgrade
|
Total Assets | 28,642 | 18,550 | 12,864 | 11,284 | 9,250 | Upgrade
|
Accounts Payable | 5,833 | 3,661 | 1,593 | 1,399 | 917.38 | Upgrade
|
Accrued Expenses | 147.65 | 123.05 | 63.21 | 43.42 | 37.42 | Upgrade
|
Short-Term Debt | 4,379 | 3,165 | 2,290 | 1,568 | 607.9 | Upgrade
|
Current Portion of Long-Term Debt | 14,402 | 8,673 | 6,339 | 5,910 | 5,691 | Upgrade
|
Current Portion of Leases | 230.65 | 117.94 | 90.41 | 71.2 | 15.36 | Upgrade
|
Current Income Taxes Payable | 203.05 | 79.91 | 26.73 | 59.55 | 34.77 | Upgrade
|
Current Unearned Revenue | 38.16 | 17.96 | 16.77 | 15.32 | - | Upgrade
|
Other Current Liabilities | 193.44 | 85.74 | 50.93 | 335.18 | 149.79 | Upgrade
|
Total Current Liabilities | 25,427 | 15,924 | 10,470 | 9,401 | 7,454 | Upgrade
|
Long-Term Debt | 47.46 | 556.02 | 852.18 | 204.83 | 405.68 | Upgrade
|
Long-Term Leases | 1,136 | 620.42 | 281.67 | 224.8 | 26.27 | Upgrade
|
Other Long-Term Liabilities | - | - | 0 | - | - | Upgrade
|
Total Liabilities | 26,610 | 17,101 | 11,604 | 9,831 | 7,886 | Upgrade
|
Common Stock | 252 | 252 | 279.04 | 240 | 240 | Upgrade
|
Additional Paid-In Capital | 237.41 | 237.41 | 277.5 | 277.5 | 277.5 | Upgrade
|
Retained Earnings | 1,713 | 1,131 | 901.63 | 948.62 | 847.4 | Upgrade
|
Treasury Stock | -171.64 | -171.64 | -198.69 | -14.4 | - | Upgrade
|
Total Common Equity | 2,031 | 1,449 | 1,259 | 1,452 | 1,365 | Upgrade
|
Minority Interest | 0 | 0 | 0.39 | 1.77 | 0 | Upgrade
|
Shareholders' Equity | 2,031 | 1,449 | 1,260 | 1,453 | 1,365 | Upgrade
|
Total Liabilities & Equity | 28,642 | 18,550 | 12,864 | 11,284 | 9,250 | Upgrade
|
Total Debt | 20,195 | 13,133 | 9,853 | 7,979 | 6,746 | Upgrade
|
Net Cash (Debt) | -19,359 | -12,002 | -9,312 | -7,510 | -6,475 | Upgrade
|
Net Cash Per Share | -19.21 | -11.91 | -9.24 | -5.77 | -5.78 | Upgrade
|
Filing Date Shares Outstanding | 1,008 | 1,008 | 1,008 | 1,226 | 1,120 | Upgrade
|
Total Common Shares Outstanding | 1,008 | 1,008 | 1,008 | 1,226 | 1,120 | Upgrade
|
Working Capital | 47.06 | 12.98 | 41.39 | 276.74 | 437.88 | Upgrade
|
Book Value Per Share | 2.02 | 1.44 | 1.25 | 1.18 | 1.22 | Upgrade
|
Tangible Book Value | 1,813 | 1,230 | 1,229 | 1,436 | 1,358 | Upgrade
|
Tangible Book Value Per Share | 1.80 | 1.22 | 1.22 | 1.17 | 1.21 | Upgrade
|
Land | 93.75 | 93.75 | 93.75 | 93.75 | 93.75 | Upgrade
|
Buildings | 847.39 | 807.75 | 724.3 | 692.7 | 654.85 | Upgrade
|
Machinery | 969.85 | 828.47 | 648.61 | 612.95 | 539.63 | Upgrade
|
Construction In Progress | 210.77 | 427.51 | 944.81 | 242.88 | 219.92 | Upgrade
|
Updated Feb 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.